Kras Mutation in Lung Cancer Patients: A Poor Prognostic Factor but Not A Predictive Factor of Egfr-Tki and Chemotherapy?

J. -I. Guan,W. -Z. Zhong,S. -J. An,J. Su,Z. -H. Chen,Y. Huang,H. -H. Yan,Z. -M. Huang,X. -C. Zhang,Y. -I. Wu

DOI: https://doi.org/10.1016/s0923-7534(20)32051-2

IF: 45.3

2012-01-01

Journal of Clinical Oncology

Abstract:e18090 Background: At present, prognostic and predictive value for KRAS mutation in lung cancer patients remains to be controversial. Biases in disease stage, treatment regimens and small scale patient population led to inconsistent results in previous studies. Methods: we collected 91 consecutive lung cancer patients with KRAS mutation detected in Guangdong Lung Cancer Institute from January 2007 to may 2010. And each patient with mutant KRAS was paired randomly to a patient with KRAS/EGFR wild-type and a patient with mutant EGFR according to the identical TNM stage. All patients were followed up for treatment regimes, tumor response, progression-free survival (PFS) and overall survival (OS). Results: The patients with KRAS mutation were associated with a significantly shorter overall survival compared with patient without KRAS mutation (P=0.0005), and the same trend of disease free survival was also found in R0 resected lung cancer patients (P=0.039). Multivariate analyses proved the status of KRAS mutation was an independent prognostic factor (HR=2.69, 95%CI: 1.91-3.80, P=0.0005). No difference was found in PFS and tumor response between the first or second line EGFR-TKI treated patients harboring KRAS mutation and KRAS/EGFR wild-type (The first line: P=0.23, 0.82; The second line: P=1.00, 0.48). In the first and second line chemotherapy, there was no significant difference for PFS among the three groups (P=0.15, 0.52). Conclusions: KRAS mutation was a poor prognosis factor, but not an independent predictive factor for EGFR-TKI and chemotherapy in lung cancer patients. EGFR wild-type is major reason for resistant to EGFR-TKI in patients with KRAS mutation.